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A PROPOSED STUDY OF SUPERVISED INJECTION 
ON BOSTON’S “RECOVERY ROAD” 
ANDREW EDWARD OLSEN 
ABSTRACT 
Supervised Injection Facilities (SIFs) for the medical supervision of illicit drug use exist 
in Europe, Canada, and Australia to reduce infectious disease transmission, overdose 
deaths, and other harms of drug use. They have been shown to reduce rates of needle 
sharing by 69% and local overdose mortality by 35% without increasing rates of drug use 
or related crime. In light of increasing rates of illicit opioid use and overdose death in 
Massachusetts, the Massachusetts Medical Society recently endorsed opening a SIF in 
Boston.  
 
This thesis proposes a study of the Boston SIF with the hypothesis that higher SIF 
utilization will be associated with decreased incidence of fatal overdose, HIV 
seroconversion, and HCV seroconversion during the study period. I propose evaluating 
this hypothesis prospectively by following clients of the SIF at 6 month intervals and 
comparing the rates of overdose death and HIV or HCV seroconversion among frequent 
and infrequent clients of the SIF. Based on data reported from previous SIFs and 
projections of the population of people who inject drugs (PWID) in Boston, a study with 
this design should detect a significant difference in these three primary endpoints 
between people using the SIF frequently and those using it infrequently within five years. 
A positive finding would confirm the efficacy of SIFs in harm reduction and secondary 
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prevention for Opioid Use Disorder (OUD), potentially leading to broader adoption in 
other hotspots of opioid use in the United States. 
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INTRODUCTION 
Background 
Opioids are a class of chemicals that include morphine, codeine, heroin, fentanyl, and 
oxycodone, among others.1 They interact with endogenous opioid receptors on the 
surface of nerves to suppress activity in the human nervous system.1 They have the 
potential to decrease consciousness, relieve pain, and cause euphoria, as well as slow the 
intestines, the heart, and the respiratory rate. Many opioids have been developed for 
medical use to relieve pain, but these medicines are frequently misused for their euphoric 
effects.1, 2 When taken in sufficient quantities, opioids can decrease the respiratory rate 
enough to deprive the brain of oxygen, leading to brain damage and death.  
 
Opioid use disorder (OUD) is a chronic, relapsing illness defined by loss of control over 
opioid use, negative consequences of opioid use, and physiologic adaptation to opioid 
use.2 Incidence of illicit opioid use in the US began increasing in the 1990s3 in parallel 
with increasing availability of prescription pain relievers,4 leading to an increase in 
accidental overdoses. Between 2000 and 2014, deaths from opioid overdose tripled in the 
United States and drug overdoses surpassed motor vehicle accidents as the leading cause 
of accidental death in the United States.5 Life expectancy in the United States decreased 
for two years in a row in 2015 and 2016 driven by increasing mortality from 
unintentional injuries6,7 as fatal opioid overdoses continued increasing from 28,647 in 
2014 to 42,249 in 2016.8 In 2015, roughly 2.4 million Americans, or 0.9% of those over 
age 12, suffered from an OUD.9  
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Aside from overdose death, misuse of injection opioids can lead to transmission of 
infectious diseases, such as human immunodeficiency virus (HIV) and viral hepatitis.10 
OUD is also frequently comorbid with psychiatric illness and suicidality, contributing to 
further morbidity and mortality not represented in overdose death statistics.11 Given these 
elevated risks, the rate of early death is 20 times higher among people with OUD.2  
 
For people with OUD seeking treatment, the opioid agonists methadone and 
buprenorphine have proven to be the most effective treatments for managing opioid 
withdrawal and cravings, preventing relapse, and reducing mortality.12  
 
Among people with OUD not yet in treatment, harm reduction approaches have been 
shown to prevent negative sequelae of opioid use.13 One harm reduction approach is the 
medical supervision of injections, which has occurred since the 1980s at Supervised 
Injection Facilities (SIFs). At such facilities, people who inject drugs (PWID) are 
provided with sterile injection equipment, monitored to prevent fatal overdose, counseled 
about the risks of injection drug use, and referred to addiction treatment. The first North 
American SIF in Vancouver has been well-studied and shown to reduce risky behaviors 
associated with HIV and HCV transmission, such as needle sharing14 and unprotected 
sex,15 and decrease the local rate of overdose death.16 
		 3 
Statement of the Problem 
The United States is experiencing the worst epidemic of drug use in its history.4 Fatal 
opioid overdoses have increased from 8,050 per year in 1999 to 42,246 in 2016.8 
Meanwhile, increased injection drug use has been tied to a 3.5-fold increase in the rate of 
acute HCV from 2010 to 201617 and to recent outbreaks of HIV in Indiana18 and 
Massachusetts.19  
 
SIFs have been shown to reduce local overdose death,16 and decrease risky behaviors for 
HIV and HCV transmission14 but no study has prospectively evaluated whether SIFs can 
decrease the incidence of infectious disease transmission or overdose death among their 
clients. 
 
In 2017, the Massachusetts Medical Society endorsed opening a SIF to help combat the 
state’s opioid epidemic.20 
 
Given the epidemic of opioid use in the United States and the strong but incomplete 
evidence for Supervised Injection Facilities in the prevention of disease transmission and 
overdose death, a study of this proposed SIF is warranted to determine whether medical 
supervision of opioid injections is a viable public health intervention in the United States. 
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Hypothesis 
More frequent use of Boston’s SIF will be associated with a decreased rate of fatal 
overdose, HIV seroconversion, and HCV seroconversion. 
 
Objectives and Specific Aims 
The objective of this proposed study is to determine whether use of a SIF has a direct 
protective effect on people who inject drugs. Opioid overdose, HIV seroconversion, and 
HCV seroconversion are among the most dire and costly consequences of opioid use. 
Therefore, this study will focus on these three primary endpoints. In order to determine 
whether HIV or HCV seroconversion have occurred, participants will be screened at 6 
month intervals using a rapid point of care combined HIV and HCV antibody test, to be 
confirmed by laboratory testing if positive. In order to determine whether fatal overdose 
has occurred, all participants will also consent to the sharing of information between the 
state medical examiner and the study in the event of their death. To determine if 
secondary endpoints such as treatment uptake, bacteremia, endocarditis, and skin or soft 
tissue infections have occurred, all participants will be screened for changes in their 
medical history at six month intervals and will consent to the sharing of outside medical 
records with the study, including information relating to drug use and HIV treatment. 
 
The specific aims of this study are as follows: 
• To determine the rate of overdose death among clients of a Boston SIF 
		 5 
• To determine the rate of HIV seroconversion among clients of a Boston SIF 
• To determine the rate of HCV seroconversion among clients of a Boston SIF 
• To assess whether an association exists between frequency of SIF use and the 
above rates 
 
		 6 
REVIEW OF THE LITERATURE 
Overview of Opioid Use Disorder 
History of Opioid Use and the Current Epidemic 
Opium was known to the earliest western physicians and may have been cultivated for 
several millenia before then. The first unequivocal reference to opium as a medicine 
occurred in Greece around 300 B.C.E..21 Sumerian cuneiform tablets from as early as 
2000 to 5000 B.C.E. describe a recipe that some scholars have interpreted as a method for 
distilling opium from the seed pod of the poppy plant.22, 23  
 
Since their first discovery, opioids have posed a paradox for both the medical community 
and society at large; they offer unparalleled analgesic and euphoric effects but these 
effects can be so profound that users must also accept a risk of addiction and overdose. 
This paradox was evident as early as the second century C.E. when the prominent Roman 
physician Galen was both a strong proselyte for the use of opium as a medicine21 and the 
first to record an opium overdose.24 Many technological advances have changed the way 
that opioids are formulated or delivered since then, leading to shifts in the perceived risks 
of opioid use, but few have changed the fundamental tradeoff between the desired and 
undesired effects of opioids.  
 
An important example of this – how advances have promised safer opioids but failed to 
deliver – is America’s lesser known first opioid epidemic. Until morphine was first 
isolated around 1805 by the German pharmacist Sertürner, opioids were primarily 
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consumed in the west as laudanum, a solution of opium in alcohol.21 However, prior to a 
scientific understanding of the chemistry of opium, recipes for laudanum were 
idiosyncratic and called for unusual ingredients such as pearls, coral, bezoars from a 
cow’s intestine, stag heart, and even unicorn.25 When the Merck company began 
producing morphine in 1827 and codeine in 1836, the improved purity of these 
substances made them a great deal safer and more standardized than prevailing 
formulations of opiates.22 Thus, they were quickly taken up by physicians and patients 
eager for predictably effective treatments for pain, diarrhea, and a number of other then-
intractable medical problems.4 
 
As would later be repeated, a revolutionary development in the science of opioids had 
made them easier and safer to use but had done little to dampen their potential for causing 
addiction. Although data about actual use of opiates is lacking from this early time 
period, the supply of opium and morphine in the United States was sufficient to support a 
prevalence of opioid addiction of 0.072% in the 1840s.4 Over the next 50 years that 
number would increase by an order of magnitude with the development of the 
hypodermic syringe, the proliferation of unlabeled opiates in patent medicines for 
coughs, diarrhea, and pain, and the Civil War leaving hundreds of thousands wounded.24 
By the 1890s the supply of opioids would peak, supporting an estimated prevalence of 
opioid addiction of 0.459%.4 Though this estimated prevalence was still less than half 
contemporary rates of OUD,9 opioid addiction was an important issue before the 
Massachusetts Medical Society in 1860 as in 2018. At that year’s annual meeting, Dr. 
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Oliver Wendell Holmes remarked that “a frightful endemic demoralization betrays itself 
in the frequency with which the haggard features and drooping shoulders of the opium 
drunkards are met with in the street.”26  
 
By the beginning of the 20th century, new non-addictive analgesics and anti-diarrheals 
had been discovered, making opioids less important in the medical armamentarium.4 
Meanwhile, public and professional opinion swung against opioids and the patent 
medicines that contained them. Additionally, a series of new regulations were enacted in 
the early 1900s to restrict their supply. First, the Pure Food and Drug Act (1906), which 
presaged the creation of the FDA, established a labeling requirement for any product 
containing opium or morphine.27 Then, the Harrison Narcotics Act (1914) established 
taxes on opium and cocaine derivatives and substantially narrowed their legal use, 
including by physicians.28 By the 1920s, the opioid supply in the US had returned to a 
lower level, capable of supporting an opioid addiction prevalence of no more than 
0.197%, less than half the peak supply in 1890.4  
 
However, by the 1980s and 90s, memory of this first opioid crisis had faded. With the 
development of new opioid analgesics like oxycodone came research suggesting they 
could be used for treatment of chronic non-malignant pain without a substantial risk of 
addiction.29, 30  Within a few years, a major campaign by the American Pain Society to 
acknowledge pain as the “Fifth Vital Sign” swept through the healthcare system leading 
to more liberal administration of opioids to patients with complaints of pain.4 In the 
		 9 
context of extensive payments from opioid producers to physicians and heavy advertising 
suggesting that newer opioids had lower potential for addiction,31 prescription opioids 
became the solution to America’s pain problem.4  
 
Thus began the first phase of the modern opioid epidemic: a gradual 15-year increase in 
the overdose death from prescription opioid pain relievers, from roughly 1 death per 
100,000 in 2000 to roughly 4 per 100,000 in 2015.5 There is a strong relationship 
between this increase in opioid deaths 
and increased availability of legal 
prescription opioids (Figure 1); there 
are concomitant increases in opioid 
sales, opioid treatment admissions, and 
opioid deaths.4  
 
Even people using opioids as directed 
can experience a deadly overdose. 
Thus, the connection between opioid 
sales and opioid overdose in this data fails to discern the individual contributions of 
medical and illicit use to increasing overdose deaths. However, other studies have shown 
that as prescription opioids increased in availability during the 1990s and 2000s, they 
became the primary gateway to Opioid Use Disorder (OUD). In one study of people with 
OUD, participants who began using opioids in the 1960s were four times more likely to 
Figure	1.	From	Kolodny	et	al,	2015.	Increases	in	opioid	sales,	deaths,	and	treatment	admissions,	1999-2010.	
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start with heroin than with prescription opioids, in the 1990s these numbers equalized, 
and by the 2000s people who would later be diagnosed with OUD were three times more 
likely to start with prescription opioids than with heroin.32 In another study of over 1 
million patients receiving opioid prescriptions for the first time between 2006 and 2013, 
the likelihood of chronic opioid use increased with each additional day of medication 
supplied after the third day and the risk of opioid use at 1 year doubled with the first 
refill.33 Although this study evaluated chronic opioid use as prescribed, the findings 
corroborate other data suggesting that even brief prescriptions of opioids in the early 
2000s led to long term use. 
 
A second phase of the opioid epidemic began around 2010. By that time, it was clear that 
widespread availability of prescription opioids was fueling an epidemic of illicit use and 
overdose and the supply of prescriptions began to contract. The per capita supply of 
prescribed opioids in the US peaked in 2010 and subsequently dropped nearly 20% by 
2015, though still remaining roughly three times higher than in 1999.34 At the same time, 
opioid producers attempted to address illicit use by introducing formulations of oral 
opioids whose pharmacokinetics made them difficult to inhale or inject, such as the abuse 
deterrent formulation (ADF) of Oxycontin, which was introduced in 2010. Unfortunately, 
substantial reductions in injection or inhalation of oxycodone among people with OUD 
after the introduction of the ADF were largely attributable to exclusive abuse by the oral 
route or migration to heroin.35 
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Heroin deaths increased accordingly as opioid prescriptions declined, more than tripling 
from 2010 to 2014.36 In 2013, the incidence of new heroin use was 19 times higher 
among people who had used prescription opioids recreationally than among people who 
had not.37 Starting in 2013, deaths due to the highly potent synthetic opioid fentanyl 
began growing exponentially and have doubled each year, up to the most recent data in 
2016.8, 38 In 2016, overdose deaths from synthetic opioids like fentanyl surpassed 
prescription opioid overdose deaths; there were 19,413 synthetic opioid overdose deaths, 
compared with 17,087 due to prescription opioids and 15,469 involving heroin.39  
 
To summarize, these studies suggest a pattern of widespread prescription opioid use 
beginning in the 1990s and 2000s that introduced a number of future addicts to opioids 
for the first time. As sales increased, both medical and non-medical use of opioids 
contributed to increases in lethal drug overdose. In the 2010s, new restrictions came into 
place to deter illicit use of pharmaceutical opioids and overdose death from cheaper street 
opioids like heroin became more prevalent. Then in 2013, overdose deaths due to 
fentanyl began to rise exponentially as this new illicit synthetic opioid began to be cut 
into heroin and other illicit drugs, surpassing prescription opioid overdose deaths by 
2016. As the opioid epidemic reached a crisis level nationally, Massachusetts was 
experiencing an even higher rate of 33.0 drug overdose deaths per 100,000 compared to 
the national average of 19.8 per 100,000.8 In the most recent data from 2016, 42,249 
people in the US died due to opioid overdose,8 2,083 of whom were Massachusetts 
residents, and 193 of whom lived in Boston.40  
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Pathophysiology of Opioid Use Disorder 
LeMoal and Koob describe a basic psychiatric model of addiction, which posits that 
substance use begins with high-seeking and progresses with repeated use to low-
avoidance.41 A drug user may experience euphoria when trying a drug for the first time, 
an experience that “pulls” them back to use again seeking that high. However with 
recurrent use, adaptation to the substance begins to make time without it dysphoric for 
the drug user, “pushing” them to use in order to avoid lows. 
 
This theory synergizes well with a neurobiological model of addiction, called the 
opponent-process model, which posits that each process in the body has at least one 
opponent-process that acts against it to maintain homeostasis. In the case of addiction, 
this theory proposes that the opponent-process to the one overstimulated by the drug 
becomes upregulated over time, decreasing the pleasure obtained from each successive 
use, and making periods between use more and more uncomfortable (Figure 2).41 
 
Neurobiologic studies have 
demonstrated that opioid use 
stimulates opioid receptors 
throughout the body causing 
analgesia, euphoria, and slowing the heart, lungs, and intestinal tract.42 With repeat use, 
opioid receptors become downregulated to adjust to a new homeostatic point with a 
Figure	2.	Opponent-process	upregulation	leading	to	dysphoria.	From	LeMoal	&	Koob,	2007.	
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higher average receptor occupancy.42 Consequently, between periods of opioid use when 
exogenous opioids are absent from the synaptic cleft, the signals from these nerves are 
below normal. This hypoactivity of opioid-stimulated nerves manifests in the opioid user 
as dysphoria, miosis of the pupils, piloerection (goose bumps), tachycardia, tachypnea, 
diarrhea, myalgias, and hyperalgesia – the clinical syndrome of opioid withdrawal.43  
 
Opioid-induced hyperalgesia, an important negative effect of opioid use through which 
previously benign stimuli become noxious ones, provides an illustrative example of the 
problematic effects of opponent-process upregulation.44 Daily administration of heroin to 
rats for only 12 days caused a long-lasting increase in pain sensitivity to paw pressure, 
worsening with each injection although the amount injected remained constant (Figure 
3).45 Even abstinent heroin-exposed rats whose pain tolerance had returned to normal 
experienced a return of long-lasting hyperalgesia with a single dose of heroin small 
enough to have no effect on heroin-naive rats.45  
 
 
 
 
 
 
These findings illuminate the challenges faced by repetitive opioid users, even those that 
used them briefly, and support the characterization of OUD as a chronic, relapsing 
Figure	3.	Long-lasting	hyperalgesia	from	heroin	administration	in	rats.	From	Celerier,	2001.	
		 14 
disease. Onset of painful hyperalgesia is swift with early use and worsens over time. The 
decrease in pain sensitivity back to baseline is slow after remission. And, even after a 
former user has returned to baseline, a single small dose of opioids is sufficient to bring 
on painful hyperalgesia that can last for days. In light of these findings, it is hardly 
surprising that relapse rates higher than 90% following opioid detoxification have been 
reported.46 
Definition of Opioid Use Disorder 
In 2013 the DSM-5 was released by the American Psychiatric Association with important 
updates to issues of substance use. It unified the previously separate diagnoses of 
“Substance Abuse” and “Substance Dependence” into a single, broadly applicable 
diagnosis of “Substance Use Disorder.” 
 
This new definition succinctly encapsulated a wide spectrum of psychiatric and social 
problems related to use of any substance without using stigmatizing language and also 
included some “substance-less addictions” with a similar pathophysiology, such as 
gambling.47 There are eleven new criteria for Substance Use Disorder under the DSM-5 
(Table 1). Notable changes in the definition of substance use disorder include replacing 
the older, potentially stigmatizing terminology of “drug abuse” and “drug dependence” 
included in the DSM-IV and adding “craving” as a new criterion. With withdrawal or 
tolerance excluded as positive criteria for medicines being used as prescribed, people 
whose substance use meets 2-3 criteria are said to have Mild Substance Use Disorder, 
while substance use meeting 4-5 criteria is described as Moderate and 6 or more as 
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Severe. People can suffer from multiple substance use disorders simultaneously and to 
varying degrees, such as Moderate Tobacco Use Disorder and Severe Opioid Disorder. 
This new approach to the diagnosis of substance use disorders describes the salient 
characteristics of addiction without the use of stigmatizing language and has the 
advantage of broad applicability across any number of substances.  
 
Table 1: DSM-5 Criteria for Substance Use Disorder (Hasin, 2013) 
 2-3 criteria in 12 months = Mild SUD, 4-5 criteria = Moderate, 6+ criteria = Severe  
Loss of Control 
Use in larger amounts or for longer times than intended 
Repeated attempts to quit or control use 
Craving 
Risky Use 
Hazardous Use 
Physical or psychological problems related to use 
Social Impairment 
Social or interpersonal problems related to use 
Major roles neglected due to use 
Excessive time spent using or accessing substance 
Important activities given up due to use 
Physiologic Adaptation 
(unless used as prescribed) 
Withdrawal 
Tolerance 
 
Prevention and Treatment of Opioid Use Disorder 
Efforts to prevent OUD focus on widespread education of both laypeople and medical 
practitioners about the addictive potential of opioids,48, 49 decreasing the availability of 
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opioids while increasing availability of alternatives,48 and improving surveillance of 
prescription opioids to detect early use disorders before they increase in severity.48, 49, 50 
 
Treatment of people with OUD is as important as prevention and arguably more 
challenging. Prior to remission or during relapses, the key to the safety of people with 
OUD is reducing harms associated with use.51 Pre-exposure prophylaxis can reduce the 
rate of HIV infection among people who inject drugs52, 53 while needle exchanges can 
decrease the rates of HIV,54 HCV,51 and other injection-related infections.55 Widespread 
naloxone distribution has been shown to decrease the rate of overdose death.56 SIFs can 
decrease the rates of overdose death and all injection-related infections while offering 
pathways to addiction treatment, as discussed in the subsequent section.16, 57 
 
For patients who are interested in ceasing illicit use of opioids, agonist therapy with 
methadone or buprenorphine is the most effective treatment for opioid withdrawal. 
Agonist therapy also helps maintain people with OUD in remission, significantly 
reducing mortality from OUD.2 Although agonist therapy is among the most effective 
treatments available, for patients who wish to avoid opioid agonists, there are effective 
non-opioid treatments for the symptoms of withdrawal.2 For maintaining recovery in 
patients who prefer complete opioid abstinence, naltrexone is an opioid antagonist 
available in a long-acting formulation that may promote abstinence and recovery by 
blocking the ‘high’ of illicit opioids and offering relief of cravings for some patients.2  
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Existing research on Supervised Injection Facilities 
The concept of creating a legally sanctioned space to inject drugs using sterile equipment 
in the presence of medical professionals was first introduced in Switzerland in the 1980s, 
once it became clear that injection drug use was an important contributor to the spread of 
HIV.57, 20 As the HIV epidemic continued into the 1990s these spaces proliferated across 
Europe, resulting in more than 90 locations today offering a diverse array of services, 
including on-site detoxification and residential treatment programs, social work and peer 
counseling, on-site primary care services, and facilities for the supervised smoking of 
drugs.58, 59 
 
In the early 2000s SIFs spread outside of Europe when the governments of Canada and 
Australia each granted legal waivers to a single SIF for the purpose of studying its 
effectiveness. The hundreds of studies performed at these facilities in Vancouver and 
Sydney now form the bulk of the medical literature surrounding SIFs.58 More recently a 
secret SIF has begun operating at an undisclosed location in the United States,60 and 
several other US cities including New York, Seattle, San Francisco and Philadelphia are 
weighing the possibility of opening official SIFs.61 
 
An important systematic review by Potier et al in 2014 synthesized 75 articles about SIFs 
to find that they decreased overdoses while promoting safer injection and access to 
medical treatment, especially among marginalized PWID, while avoiding the moral 
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hazard of increased overall injection.58 Despite concerns that SIFs would attract more 
drug users to their neighborhoods, studies demonstrated decreased public injection and 
drug related litter.58  
 
Vancouver’s Insite SIF was granted temporary legal exemption to Canada’s Controlled 
Drugs and Substances Act under the condition that its impacts be thoroughly evaluated;62 
accordingly Vancouver has been the source of a large body of evidence regarding SIFs, 
making Insite the best studied SIF to date.58 In reviewing the evidence from Vancouver, it 
is important to note the potential for bias given the potential that Insite could be closed if 
evidence supporting its efficacy was not produced. However, many of the findings from 
Insite have been corroborated by evidence from other SIFs around the world. 
 
The SEOSI (Scientific Evaluation of Supervised Injection) cohort of over 1,000 
Vancouver SIF clients has been followed since 2003, producing evidence that Insite 
improved access to medical treatment. One study of this cohort showed that the SIF 
improved access to treatment for soft tissue infections; SIF nurse referrals led to 
hospitalizations (aHR 5.49 for hospitalization if referred vs not referred, 95%CI 3.48-
8.67) and significant shorter hospitalizations (4 days [IQR 2-7] vs 12 days [IQR 5-33] if 
not based on referral, p<0.001).63 A before-after study of this same cohort showed that 
the SIF also improved access to addiction treatment; the opening of the Vancouver SIF 
was associated with an increase in detoxification among cohort participants (OR 1.32 
after compared to before opening, 95%CI 1.11-1.58), which in turn was associated with 
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decreased SIF use (24 visits vs 19 visits, p=0.02) and increased uptake of methadone 
maintenance (RH 1.56, 95%CI 1.04-2.34) and other addiction treatment (RH 3.73, 
95%CI 2.57-5.39), comparing those who entered detox through Insite to those who did 
not.64  
 
This association between SIF use and addiction treatment uptake was only partially 
corroborated by a study of Sydney’s Medically Supervised Injecting Centre (MSIC) 
which showed that more frequent attendance of the SIF was significantly associated with 
higher referral rates for addiction treatment (RH 1.6 compared with infrequent attendees, 
95%CI 1.2-2.2) but not with higher rates of confirmed treatment uptake (OR 0.8 of 
frequent attendance comparing confirmed vs unconfirmed uptake, 95%CI 0.4-2.0).65 
However, the study’s method made it challenging to confirm uptake, requiring clients to 
keep a blank study form while awaiting their appointment, then present it to the referred-
to service to be filled out and mailed back. With too few uptakes confirmed among both 
frequent and infrequent SIF users, the study was ultimately underpowered to disprove the 
association between SIF use and addiction treatment uptake reported by Wood.  
 
A number of studies of the Vancouver SIF have also demonstrated its positive effect on 
needle sharing behavior. A 2005 study of the Vancouver Injection Drug Users Study 
(VIDUS) cohort showed that use of the SIF was independently associated with decreased 
syringe sharing compared with non-SIF use (OR 0.30, 95%CI 0.11-0.82).66 A SEOSI 
study from the same year showed that among HIV-negative participants, exclusive SIF 
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users reported lower rates of needle sharing compared to non-exclusive SIF users (OR 
0.14, 95%CI 0.00-0.78); this finding was not significant among HIV-positive 
participants.67 A 2007 follow up survey of injection practices in the SEOSI demonstrated 
that those using the SIF for more than 25% of reported injections were more likely than 
infrequent users to report reusing syringes less (OR 2.16, 95%CI 1.48-3.16), injecting in 
a clean place (OR 3.00, 95%CI 2.22–4.06), and disposing of syringes safely (OR 2.22, 
95%CI 1.54–3.20).68  
 
These findings from Vancouver are corroborated by a study from Barcelona that found 
young PWID reporting no syringe borrowing were 3.3 times more likely than those 
reporting borrowing to have used a SIF (OR 3.3, 95%CI 1.4-7.7).69 Taking this study and 
several from Vancouver together, two of the Vancouver investigators performed a small 
meta-analysis showing that SIF use was associated with an OR of 0.31 (95%CI 0.17-
0.55) for syringe sharing, though they had to define SIF use and syringe sharing broadly 
to capture studies with different terminology.14 
 
Given that SIF use has been associated with decreased syringe sharing,14 increased 
condom use,15 and increased addiction treatment uptake64 several models have projected 
that it should also prevent HIV and HCV transmission. At the high end a 2008 model 
estimated 1,517 HIV and 54 HCV infections prevented over ten years,70 though this 
model has been criticized for significantly overestimating the incidence of HIV among 
PWID.71 A more conservative 2010 article used four models to estimate 35 (95%CI 19-
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57) HIV infections prevented per year.72 However, it too has been criticized for 
assumptions and mathematical errors made; in re-doing the calculations a more 
conservative study estimated 5-6 (95%CI 4-8) HIV infections prevented per year.73 
Underlying the controversy over the efficacy of SIFs for HIV and HCV prevention is the 
fact that no studies have directly shown a decreased rate of HIV or HCV seroconversion 
associated with SIF use. 
 
Finally, despite millions of supervised consumptions and thousands of treated overdoses, 
there has never been a single death reported at a SIF.59, 74, 75 Based on 1,004 observed 
overdoses without a fatality over the first 4 years of Insite’s operation, the Vancouver 
team used three models to estimate how many overdose deaths the SIF had averted, 
yielding a range of 1.9 to 11.7 averted deaths per year.76  
 
In addition to simulated overdose death prevention, several observational studies have 
established a spatial relationship between the presence of an open SIF and the likelihood 
of overdose and death. One before-after study noted a 68% decrease in ambulance calls 
for overdoses in the 3.6km2 area surrounding the Sydney SIF after it first opened and an 
80% decrease in its immediate 2.6km2 vicinity during operating hours.77 Extending these 
findings not just to overdoses but to fatal overdoses, the Vancouver team determined that 
there was a 35.0% reduction in overdose mortality within a 500m radius of the 
Vancouver SIF by comparing fatal overdoses in the 2 years before it opened to the 2 
years after. This reduction from 253.8 to 165.1 deaths per 100,000 person-years was 
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significant (p=0.048) and the rate difference between the SIF locality and the rest of 
Vancouver was also significant (p=0.049).16 Although these ecological studies suggest a 
relationship between the local presence of an open SIF and a decreased risk of overdose 
death, no studies have observed whether SIF clients are themselves protected from 
overdose death by using the SIF or whether another mechanism explains the local effects 
of SIFs on overdoses. 
 
Although many studies of SIFs have evaluated their effect on overdose mortality, they 
have all been ecological studies of the areas surrounding SIFs or simulations of deaths 
that might have occurred without the intervention of SIF personnel. None have 
prospectively evaluated the direct protective effects of the SIF on its clients relative to 
people who inject drugs without attending a SIF. Likewise, although SIFs have been 
shown to reduce risk factors for HIV and HCV transmission in multiple studies, SIF 
clients have not been shown to have lower rates of HIV or HCV infection than other 
PWID.  
 
SIFs must be studied more rigorously to determine whether they can significantly reduce 
morbidity and mortality from the current opioid epidemic in Massachusetts and the 
United States. This thesis proposes a mechanism for studying the effectiveness of a SIF 
for the prevention of overdose death, HIV, and HCV based on the Massachusetts Medical 
Society’s suggestion to establish a SIF in Massachusetts.20 
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METHODS 
Study design 
In light of the success of SIFs worldwide and the worsening crisis of opioid addiction in 
the Massachusetts, which claimed 2,069 lives by overdose alone in 2016,40 the 
Massachusetts Medical Society recently endorsed the concept of a pilot SIF.20 They 
advocated lobbying for state and federal exemption to expand an existing Supportive 
Place for Observation and Treatment (SPOT) into a full SIF. Only one SPOT exists in the 
state, which has been operational at Boston Healthcare for the Homeless Program 
(BHCHP) since August 2016. Located at the intersection of Massachusetts Avenue and 
Albany Street in an area known for its high density of addiction treatment programs, it 
offers drug users a place to receive medical observation and supportive care while high.78 
Unlike a SIF the SPOT does not allow clients to use drugs on-site and does not assist 
them in procuring sterile equipment prior to injecting.78 This study will be a prospective 
cohort study of people who inject drugs based at this proposed Supervised Injection 
Facility.  
 
It would be unethical to withhold access to the SIF for the purposes of better studying a 
treatment known to protect against overdose mortality, so a randomized study is not 
feasible. However, since each “safer” injection at the SIF should incrementally decrease 
the injector’s cumulative risk of new infection and death from overdose, it should be 
possible to measure the effect of the SIF within a single cohort. Clients who use the SIF 
for a greater proportion of their injections should have a measurably lower rate of 
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injection complications due to the cumulative effects of their many safer injections, while 
clients who only use the SIF sporadically should have a rate of complications 
approximating that of non-SIF users.  
 
A protective effect due to the SIF can be supported by a significant association between 
the proportion of a client’s injections occurring under supervision at the SIF and that 
client’s likelihood of overdose death or seroconversion. 
 
Study population and sampling 
The source population for this study will be all clients of the SIF. Participants must be 18 
or older and non-pregnant, use injection drugs at least daily at the time of their entry into 
the study, and have used the SIF at least once. SIF clients who are already HIV or HCV 
positive will be allowed to enroll to increase the power of the study to detect overdose 
prevention, but they will be excluded from the HIV and HCV sub-analyses, respectively. 
 
The participants must consent for their study records to be linked with BHCHP charts and 
potential death records from the medical examiner. They must also consent for the study 
to contact other hospitals or providers about care received elsewhere, including care 
related to substance use and HIV infection. They must consent to be tested for HIV and 
HCV, as all participants will receive free rapid HIV and HCV tests at each 6 month study 
visit. As additional compensation for their time, they will receive a $10 gift certificate to 
		 25 
Dunkin Donuts for each study visit. Participants would be free to enter or leave the trial 
without losing access to the SIF.  
 
Based on local public health and census data there was an estimated minimum of 7,400 
and maximum of 24,000 people who injected opioids in Boston in the past year, with half 
of those people found in the neighborhoods surrounding the proposed SIF (Appendix 1). 
Therefore, a conservative estimate is that 10,000 people inject opioids annually in Boston 
with 5000 in the South End, South Boston, North Dorchester, and Roxbury.  
 
Based on this estimated population of PWID in Boston, a study with the proposed design 
would be sufficiently powered to realistically detect the protective effects of a SIF. With 
a follow-up period of 3 years and a high censoring rate of 50% given the transient, 
marginalized study population and the increased likelihood that SIF clients will enter 
addiction treatment,79 436 participants would be needed to confirm expected decreases in 
HCV seroconversion. Incidence of HIV is much lower than that of HCV among PWID so 
1,422 participants would be needed with the same follow-up period to confirm the 
expected decrease in HIV seroconversion in this study. Given the smaller expected effect 
of supervised injection on overdose death, a sample size of 4,125 participants is required 
to confirm the expected 35% decrease in overdose in this study. (Appendix 2) 
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Intervention 
In this study, all subjects will have received the intervention of injecting drugs at a SIF. 
At the end of the study period, they will be sorted into two equally sized groups based on 
the proportion of their injections occurring under supervision at the facility. 
 
Study variables and measures 
The primary endpoints will be death due to opioid overdose and HIV or HCV 
seroconversion. Secondary endpoints will include positive outcomes, such as 
detoxification, and addiction treatment uptake, as well as other serious complications of 
IV drug use, such as skin or soft tissue infection, endocarditis, bacteremia, and physical 
trauma secondary to intoxication or violence. The study will also collect demographic 
information to ensure that observed effects are not explained by confounding factors, 
such as race, age, and gender. The primary explanatory variable proposed is frequency of 
SIF use, so each SIF visit would be recorded, and at each visit participants would be 
surveyed about how many times they had injected drugs since their previous visit. 
 
Recruitment 
All eligible users of the SIF would be recruited into the study, although clients who 
refuse to consent for the study would still be free to use the SIF. Participants would also 
be free to leave the study without losing access to the SIF. For their participation, clients 
would receive free rapid HIV and HCV testing and counselling, and gift certificates ($10 
value) to compensate for time spent on each 6-month study visit.  
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Data collection 
Participants’ charts at BHCHP will be monitored for the primary and secondary 
endpoints listed above. At each 6-month study visit, including the first, participants 
would be screened for HIV and HCV and interviewed about their status relative to all 
study endpoints, including whether they had received care for complications of injection 
drug use at another institution. Each time a participant visited the SIF, their visit would 
be recorded, and they would be asked how many times they injected since their last visit 
to provide a rough estimate of the proportion of their injections occurring at the SIF. 
Finally, the medical examiner’s office would be contacted on a monthly basis to confirm 
and record the cause of death of any participants who had died in the intervening period. 
In order for the study to confirm reported endpoints, participants would consent for the 
study to request health information, including information about drug use and HIV 
treatment, from the medical examiner and other healthcare providers. All study data 
would be stored in RedCap to ensure privacy protection. 
 
HIV and HCV screening will be performed at the point of care with rapid fingerstick 
antibody assays from OraSure. This point of care screening strategy has the advantage of 
maximizing the likelihood of follow-up by reporting the results during the same visit, 
while minimizing the screening cost and the amount of blood drawn. Both OraSure tests 
have strong performance as screening tests. Fisher et al measured OraSure HCV’s 
fingerstick sensitivity at 92.7% (88.8-96.5%) and specificity at 99.8% (99.4-100%),80 
while Smith et al found HCV sensitivity of 99.3% (98.1-99.7%) and specificity of 99.5% 
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(98.4-99.8%).81 The OraQuick HIV1/2 Antibody screen has an HIV sensitivity of 99.6% 
(98.5-99.9%) and specificity of 100% (99.7-100%) when used with fingerstick blood.82  
 
In accordance with current expert guidelines,83, 84 positive HIV screens would be 
laboratory-confirmed with fourth generation combined HIV-1/2 antibody/antigen testing 
followed by differentiation immunoassay if positive. Positive HCV screens would be 
laboratory-confirmed with third generation ELISA for recombinant NS3, NS4, and NS5 
HCV core antigens with concurrent quantitative HCV RNA testing to confirm active 
infection. If a rapid screening test is positive, but any confirmatory test is negative, it will 
be considered a negative test result.  
 
Data analysis 
At annual intervals during the trial period and at its conclusion, participants would be 
sorted by the proportion of their injections occurring at the SIF, based on SIF injection 
records and self-reports of outside injection (see above under “Data Collection”). 
Participants would then be split at the median, into a group of ‘infrequent’ SIF users, and 
a group of ‘frequent’ SIF users.  
 
These two groups will be compared by a Cox proportional hazards model using 
Statistical Analysis Software (SAS) to assess whether observed hazard rates for overdose 
death, HIV seroconversion, and HCV seroconversion differ significantly based on 
frequency of SIF use after adjustment for confounding factors. The effect of SIF 
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attendance on secondary outcomes will be assessed by the same method. If interval data 
suggest that SIF use is associated with significantly increased harms or reduced benefits, 
or if a significant finding in all three primary outcomes is achieved prior to the projected 
end date, the trial will be stopped early. 
 
Timeline and resources 
Data from the Sydney MSIC show that over a 12 month period, 761 PWID of an 
estimated total population of 1103 PWID within a 2 mile radius injected at the facility, 
giving an estimated coverage of 70.7% of that local population.85 Given the larger 
estimated population of 5000 PWID annually surrounding the proposed SIF, an estimated 
3500 individuals would likely use the SIF in a given year, lending plausibility to a 
strategy of recruiting a total of three to five thousand participants to be followed for three 
years with an expected censoring rate of 50%. With this many participants, the study 
should be sufficiently powered to detect effects on HIV and HCV transmission within 
months and will have reached full enrollment to detect effects on overdose death within 
two years. Once at full enrollment, the study would run for an additional three years 
before a significant result for opioid overdose death would be expected. Thus, the study 
would last roughly five years. 
 
Prior to recruiting participants, the SIF would have to be established and the study design 
would have to be approved by the Boston University Institutional Review Board, which 
could take up to six months. Once IRB-approved, the study would need office space and 
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equipment, and staff would have to be hired. Given the expected study population of 
3500 in the first year, 9-10 new participants could be recruited daily. With each study 
visit taking roughly 30 minutes, at least two nurses would be needed to ensure the 
recruitment area was well staffed even when an intake was already being performed. A 
research assistant would be needed to maintain the data. By six months, participants 
would begin returning for their follow up visits, and at least one additional nurse would 
be needed. By the third year of the study, recruitment would have slowed, and more 
nursing time could be dedicated to follow up and data management. The principal 
investigator would be responsible for designing and analyzing the data set and would 
need a strong background in biostatistics. Once data collection was complete, another 6 
months would be required for data analysis and writing the manuscript. The costs for 
these personnel, and the materials they would need to perform the study add up to 
$3,116,950 over six years (Table 2). 
 
Table 2. Estimated Study Costs 
Item Estimated Unit Cost Number Needed Total Cost 
Laboratory Costs    
OraSure HIV test $10 7000/yr x 3 yrs $210,000 
OraSure HCV test $18 7000/yr x 2 yrs $252,000 
Lancets $3/100 count 15000/yr x 5 yrs $450 
Vacutainers $50/100 count 5000 $2500 
HIV fourth 
generation combined 
immunoassay 
$50 100 $5000 
HIV differentiation 
immunoassay 
$50 100 $5000 
HCV third 
generation NS3, 
NS4, NS5 ELISA 
$50 3000 $150,000 
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Office Costs    
Office space rent $2000/month 12 mo x 5 years $120,000 
Office supplies $100/month 12 mo x 5 years $12,000 
Computers $2000 5 $10,000 
Software $5000/year 1 x 5 years $25,000 
Personnel Costs    
Nursing staff $65,000/year 3 x 5 years $975,000 
Research Assistant $50,000/year 1 x 5 years $250,000 
PI/Biostatistician $125,000/year 1 x 6 years $750,000 
Participant Costs    
Gift certificates $10 x 2 per year 3500 x 5 years $350,000 
Total Costs   $3,116,950 
 
Institutional Review Board 
This study would require full IRB review as non-exempt human subjects research. It 
would go before the IRB at Boston University Medical Campus assuming the PI is a 
member of faculty there. The application would include details about the recruitment and 
counseling materials provided to participants before they consent to participation in the 
study. It would be especially important to provide detailed information about the risks of 
IV drug use, treatment options available, and the implications of positive HIV and HCV 
tests resulting from participation in the study. With the help of linguistically appropriate 
consent materials and telephone interpreters, participants would be consented in English, 
Spanish, Mandarin, Portuguese, Haitian Creole, and Portuguese Creole given the 
prevailing languages spoken in Boston.
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CONCLUSION 
Discussion 
Although the study proposed here could make a substantial contribution to the body of 
literature regarding SIFs, there are substantial obstacles that would need to be overcome 
in order for it to occur. First among these obstacles is the establishment of a SIF, which 
would require buy-in from a number of different stakeholders, followed by amendment to 
or exemption from existing laws.  
 
SIFs are controversial and they sit at the convergence of debated medical, legal, and 
social issues. As such, they must grow out of a more multilateral consensus than an 
average medical facility. In comparison to the process of establishing a new doctor’s 
office, a SIF is more likely to face objections from local officials and neighbors wary of 
its impact on the area, is more dependent on the trust and interest of the vulnerable 
population it serves, and will not be possible without the support of local law 
enforcement.  
 
In Vancouver, all of these factors aligned before the SIF was established. Years of 
consensus building and advocacy were required before the Vancouver SIF opened.86 
PWID in Vancouver were already strong self-advocates through a well-established union, 
called the Vancouver Area Network of Drug Users, that drew attention to the health crisis 
many PWID were facing.87 PWID were interested in the idea of a SIF and had already 
established a strong working relationship with the medical researchers involved in 
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organizing the SIF through VIDUS, a cohort study that followed over 1000 PWID in 
Vancouver starting in 1996.88 Local law enforcement, including the Vancouver Chief 
Constable Jamie Graham, were willing to partner with the SIF to encourage safe injection 
practices rather than discouraging safe drug use by arresting SIF clients.86 Neighbors and 
government officials from the local to national level were supportive of the effort and 
helped push through legislation to allow the SIF to operate with a special legal exemption 
to Canadian federal drug law. When that exemption expired under a conservative 
government, supporters of the SIF sued to have it extended, leading to a ruling by 
Canada’s Supreme Court that the SIF must be allowed to continue operating.89 
Unfortunately, the process is likely to be more challenging in Boston given early signs of 
opposition to the SIF from neighbors, the Boston City Council,90 and the federal 
government.91 
 
Among the largest obstacles to establishing a SIF are the legal and professional sanctions 
against medical professionals assisting with illicit drug use. According to the Trump 
administration, the Controlled Substances Act prohibits the operation of SIFs in the 
United States.91 An independent legal analysis92 has corroborated the authority of the 
federal government to interfere with a SIF, given that Section 856 of the Controlled 
Substances Act (CSA) makes it illegal to “knowingly open or maintain . . . [or] manage 
or control any place . . . for the purpose of unlawfully . . . using a controlled substance.” 
However, the same analysis suggested that states or municipalities could legally authorize 
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a SIF if the federal government decided not to interfere, following the precedent of 
needle exchanges and marijuana dispensaries.92 
  
Furthermore, medical professionals may be wary of supervising illicit drug injections 
given the risk that their medical license would be suspended, as any violation of the CSA 
constitutes a violation of the licensing regulations of the Massachusetts Board of 
Registration in Medicine.93 However, there have been signs of changing regulatory 
attitudes towards supervised injection. In Massachusetts, a bill was introduced in the 
2017-18 state senate enabling the Department of Public Health to oversee supervised 
drug consumption facilities.94 Meanwhile, on a professional front, both the MMS and its 
national counterpart the AMA have endorsed the concept of SIFs,20, 95 suggesting a 
growing consensus among physicians that SIFs are legitimate harm reduction measures. 
Of note, the Massachusetts General Laws (Chapter 94C, Section 8) already provide 
exemption for the administration of scheduled drugs to narcotic dependent people in the 
course of authorized clinical investigation, provided that evidence of federal approval is 
granted, so federal opposition to SIFs is the primary barrier to the establishment of a pilot 
SIF in Massachusetts.96 
 
Once a SIF is established, there are several logistical challenges that might limit this 
proposed study, namely securing funding and recruiting a sufficiently robust group of 
participants. A study of SIFs may face additional restrictions on funding due to the 
controversial nature of the project. In Vancouver, studies of the SIF were sponsored by 
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Health Canada, Canada’s department of public health,86 and, although the current 
administration has stated opposition to SIFs,91 a current NIH funding opportunity 
requests proposals for pilot projects that address drug abuse to prevent HIV and HCV 
transmission. If this grant was not available to a SIF, private philanthropists, who have 
filled the gap in funding research into controversial issues such as family planning,97 
might be able to assist in this arena as well. 
 
Meanwhile, the proposed study’s size may be unrealistic given the special difficulty of 
recruiting and retaining thousands of marginalized people with opioid use disorder. SIF 
users in particular experience low rates of employment98 and high rates of 
homelessness.99 They are likely to have been incarcerated68 and more likely to have an 
illegal source of income69 with 39% of SIF users in Vancouver reporting having engaged 
in sex work.100  High rates of homelessness and joblessness could make Boston SIF users 
less likely to remain in one place, while high rates of illegal activity could make them 
more likely to be taken away from the area around the SIF by law enforcement. These 
factors and more could contribute to a higher loss to follow up than anticipated, which 
could make the large group size and long follow-up period untenable. However, the 
power calculations above account for the potentially very high attrition rate typical of 
studies of PWID, allowing more than sufficient power to detect differences in the primary 
outcomes listed.  
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Some of the most widely cited SIF studies are limited by their design or have not 
identified SIF effects on patient-centered outcomes. Findings about overdose death 
prevention by Marshall and Salmon were based on ecological data showing area effects 
of SIFs on overdose, not direct effects on SIF clients.16, 77 Meanwhile, claims about HIV 
and HCV prevention have relied on extrapolation from survey data about needle 
sharing.14 Furthermore, none of these studies have been performed in the United States. 
 
In contrast, this study measures these variables directly in the population of SIF users so 
any findings provide stronger epidemiological evidence. Positive findings within this 
study should be generalizable to any SIF of comparable size serving a similar population 
of PWID and would demonstrate for the first time that SIFs can be effective in the United 
States. This could have a major impact in other similar US cities considering establishing 
SIFs, including New York City, Philadelphia, Seattle, and San Francisco. Meanwhile, the 
failure to find significant results within five years of opening the SIF would cast into 
doubt the magnitude of a SIF’s impact on overdose and infectious disease transmission 
suggested by current research. 
 
Summary 
Drug use, especially opioid use, has become an urgent public health issue in the United 
States as overdose deaths have surpassed motor vehicle accidents5 and helped contribute 
to a reduction in the national life expectancy for two consecutive years.6,7 Intravenous 
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opioid use also contributes to the spread of HIV and HCV and new clusters of HIV 
among homeless PWID have been reported in Massachusetts.19  
 
In response to the worsening opioid epidemic, the Massachusetts Medical Society has 
endorsed establishing a pilot SIF in the state.20 Previous studies have shown a 
relationship between SIFs and decreased local overdoses77 and overdose deaths,16 
increased entry into addiction treatment,64 and decreased unsafe injection practices that 
contribute to the spread of HIV and HCV.14  However, no studies have followed SIF 
clients in the United States to establish a direct link between SIF use and decreased 
overdose mortality or decreased incidence of HIV or HCV. 
 
This study would follow SIF users at a proposed SIF in Boston for five years to assess 
whether increased frequency of SIF use is associated with decreased rates of overdose 
death or infection with HIV or HCV. If implemented as proposed, this study would be the 
first of its kind in the United States and would provide higher quality evidence about 
direct effects of SIFs on their clients than the ecological studies and smaller cohort 
studies that preceded it. 
 
Public health and clinical significance 
If SIF use were shown to decrease overdose death and transmission of HCV or HIV, it 
could have a substantial impact on public health policy and on clinical guidelines for 
Substance Use Disorders. 
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Positive findings could influence public health by encouraging other localities to open 
SIFs and encouraging policy makers to fund them. Given that SIF effects on overdose 
have been shown to be local,16, 77 an appropriate public health response to further positive 
findings should be to encourage the proliferation of many small SIFs throughout the state 
rather than expansion of the Boston site. Areas of special attention in Massachusetts 
should include Lowell, Lawrence, Fall River, Brockton, and Cape Cod, which have been 
even harder hit by HIV and overdose deaths per capita than Boston.19, 40 A substantial 
amount of public health money is dedicated to HIV prevention and a smaller but growing 
amount is now dedicated to overdose prevention.101, 102 Both official and philanthropic 
public health funding could potentially become available to support the Boston SIF or 
new SIF locations.  
 
Perhaps more importantly, if the Boston SIF is found to have protective effects on its 
clients, then it can be an effective treatment in secondary prevention for OUD and could 
potentially receive funding from insurers who cover a large number of SIF clients, 
especially MassHealth plans. Lifetime costs for treatment of HIV and HCV are 
notoriously high at $379,668103 and $94,500104 respectively. Preventable infections like 
endocarditis must be treated with weeks of IV antibiotics, while opioid overdose is a 
common cause of ICU admission,105 contributing to rapidly rising costs for inpatient 
treatment of OUD complications, reaching nearly $15 billion by 2012.106 Unlike past 
ecological studies which showed area effects from a SIF, this longitudinal study design 
		 39 
would be well suited to proving direct protective effects from SIF use that could motivate 
insurers to invest in their clients with OUD by reimbursing for their care at the SIF. 
 
Since Medicaid is the most common primary payer in OUD admissions106 and with 
MassHealth switching to an ACO model, there is one ACO that already has a vested 
interest based on existing research in the SIF as proposed. Given that SIFs have known 
local area effects on overdose,16,77 the BMC HealthNet ACO could consider supporting 
the SIF proposal based on its proximity to their hospital. Ambulance calls for opioid 
overdose decreased by 80% in the area surrounding Sydney’s SIF during operating hours 
and, thus, there could be substantial savings and added efficiency in BMC’s busy 
Emergency Department with the opening of a SIF across the street. 
 
However, if federal support for SIFs is withheld then these partially federally funded 
Medicaid plans might not be allowed to invest in a SIF even if it were a cost-effective use 
of their insurance funds. In this scenario the state of Massachusetts, which already spends 
the majority of its budget on health programs,102 might consider funding the SIF to defray 
increasing costs from OUD. 
 
In summary, this study has the potential to demonstrate for the first time that Supervised 
Injection Facilities can protect their clients from three of the most costly harms of 
injection drug use: fatal overdose, HIV, and hepatitis C. If it succeeds in demonstrating 
these effects, then governments, public health philanthropists, and payors should 
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carefully consider how to expand access to supervised injection for people who inject 
drugs.
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APPENDIX 1: Population Estimates 
 
For a lower bound of the number of people injecting opioids in Boston, we can turn to a 
Boston Public Health Commission report from 2015. It reported that in 2013, there were 
10.2 male and 3.5 female unique-person treatment admissions for heroin use per 1000 
Boston residents age 12 or higher.107 According to the American Community Survey 
from the US Census, the population of Boston over 14 in 2013 was [(1-
[0.053+0.044+0.042])*629182 = 541725.702 [US Census, 2013]. Therefore there were at 
least 0.0137* 541725.702 = roughly 7400 unique people over 14 admitted for treatment 
secondary to heroin use in Boston in 2013. However, we can expect there were many 
more who never used a hospital in 2013, as well as others who may have been 
categorized under another opioid. Furthermore, opioid use has increased from 2013 to 
now, so this is a lower bound on the number of people currently injecting all opioids in 
Boston. 
 
To find a high bound on the number of people injecting opioids in Boston, we can turn to 
the 2015 Massachusetts Behavioral Health Risk Surveillance System, in which 3.7% of 
respondents reported having used any non-medical opioids in the past year.108 The 
population of Boston in 2015 was 650,281 according to the American Community 
Survey.109 Tables 3 and 4 demonstrate that the percentage of opioid-related deaths in 
Massachusetts occurring in Boston has closely followed the percentage of Massachusetts 
residents living in Boston at 9-10%.40, 109 Therefore, assuming for purposes of estimation 
that the distribution of opioid use is uniform across all populations in the state, yields 
		 42 
0.037*650281 = roughly 24,060 non-medical opioid users in Boston. Despite growth in 
the use of opioids from 2015 to present, this is still likely an overestimate of the number 
of people who currently inject opioids in Boston, since it includes use of non-medical 
opioids in all forms, including oral and inhaled opioids. 
Table 3. Percent of opioid-related deaths occurring in Boston over time 
Source: MA 
DPH, 2017 2012 2013 2014 2015 2016 
Opioid deaths 
in Boston 70 87 108 150 196 
Opioid deaths 
in MA 742 961 1361 1651 1933 
Percentage 
occurring in 
Boston 9.43% 9.05% 7.94% 9.09% 10.10% 
 
Table 4. Percent of MA population living in Boston over time 
Source: ACS, 
US Census 2012 2013 2014 2015 
Boston 
Population 619,662 629,182 639,594 650,281 
MA Population 6,560,595 6,605,058 6,657,291 6,705,586 
Boston 
Percentage 9.45% 9.53% 9.61% 9.70% 
 
For an estimate of the local prevalence of heroin use within Boston, a Boston Public 
Health Commission report in 2011 found that the South End had more than four times as 
many heroin treatment admissions per 1000 people as Boston overall, 81.1/1000 
compared to 18.9/1000.110 Cross-referencing this with 2010 neighborhood Census data,107 
we can estimate that Boston had 0.0189*617591= roughly 11700 admissions for 
treatment due to heroin use in 2010, while the South End had 0.0811*33881= roughly 
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2750, or 23.5% of the total. By the same calculation, the neighboring areas of South 
Boston, North Dorchester, and Roxbury had roughly 0.0398*33889=1350, 
0.0144*59273=854, and 0.0220*40527=892 heroin treatment admissions respectively, 
with the four contiguous neighborhoods accounting for 50.0% of Boston’s overall 
admissions. 
 
To summarize, based on local public health and census data there were an estimated 7400 
unique people in Boston who entered treatment for heroin use in 2013, there were 
roughly 24,000 people who used any kind of non-medical opioid in Boston in 2015, and 
there were roughly 11,700 heroin treatment admissions in 2010, with 50% coming from 
the South End, South Boston, North Dorchester, and Roxbury. A convenient estimate is 
10,000 people who inject opioids in Boston with 5000 in the South End, South Boston, 
North Dorchester, and Roxbury.
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APPENDIX 2: Sample Size Calculations 
 In a survival analysis, the minimum sample size for a significant finding can be 
expressed in terms of the number of observed deaths required. This calculation relies on 
the following ‘proportional hazards’ formula, where D is the number of deaths, Zα and Zβ 
are the standard normal deviations of our given α and β errors, PA and PB are the 
proportion of participants receiving treatments A and B, and ∆ is the hazard ratio of 
treatment A to treatment B.111    
D = [Zα + Zβ]2 / [PAPBln2(∆)] 
Convention sets the α error at 0.05 and the β error at 0.2 in order to guarantee a 5% 
chance of confirming a false hypothesis (i.e. Type I Error) and an 80% chance of 
confirming a true hypothesis (i.e. power). In the denominator, PA and PB are both 0.5 
given that the two groups are split at median SIF use. Finally, based on Marshall’s data 
from Vancouver,16 our best estimate is that above-median users should have 35% fewer 
overdose deaths than below-median users, giving a predicted relative hazard of ∆ = 0.65. 
Based on these numbers, 169 overdose deaths must be observed to confirm this projected 
difference between frequent and infrequent SIF users in overdose mortality rate.111  
 
To determine how many person-years of observation would be necessary to observe 169 
overdose deaths, we can turn to the literature for overdose mortality among heroin users. 
Hickman et al reported in 2003 that among average heroin users there was a 1/100 
person-year rate of overdose death.112 However, an important contributor to the increase 
in overdose deaths in Massachusetts has been contamination of the heroin supply with 
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fentanyl, which was found to have contributed to 70% of overdose deaths in 
Massachusetts in 2016 by the state’s Health Policy Commission.113 Assuming no changes 
in the potency of pure heroin since 2003, we can estimate that fentanyl adulteration has 
increased the risk of death from overdose among heroin users to 1/(1-0.7) = 3.3 per 100 
person-years. Assuming a high censoring rate of 0.5 based on the transient and 
marginalized nature of the study population, and a mean follow up period of 3 years, a 
sample size of 5027 people would be sufficient to observe 169 fatal overdoses and 
confirm a significant difference between the two study groups. 
 
HIV and HCV seroconversion are also important endpoints in this population, so the 
study should be powered to detect effects of SIF use on these variables as well. Milloy 
and Wood found a 69% reduction in needle sharing among SIF attendees.14 According to 
Pinkerton, the annual rate of new HIV infection among people who inject drugs is 
directly proportional to the number of borrowed syringes they use,114 and Irwin et al use 
the same mathematical model or HCV transmission given that HIV and HCV are 
transmitted in qualitatively the same way among people who inject drugs.115 Therefore, a 
SIF of the same scale as Vancouver should cause a 69% reduction in risk of new HIV and 
HCV infection among its users. 
 
Using the same approximation as before – that infrequent SIF users are more likely to 
resemble the pre-SIF population, while frequent SIF users are more likely to resemble 
users at established SIFs – we can estimate the minimum necessary sample size. Based 
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on the same proportional hazards calculation as above, this study should only need to 
observe 23 new cases of HIV and HCV each to confirm with 80% power that HIV and 
HCV transmission rates were 69% lower among frequent SIF users.111 However, given 
the very different incidence of HIV and HCV among PWID, different amounts of time 
would be necessary to detect the same number of new cases.  
 
Estimating a baseline event rate for HIV transmission among PWID is challenging due to 
a lack of existing literature. There is no data on contemporary HIV incidence among 
PWID in Boston, and only two studies have measured HIV incidence among PWID in 
similar northeastern cities in the past 20 years. Des Jarlais and Bruneau followed PWID 
in New York City and Montreal respectively in order to assess the impact of harm 
reduction measures such as needle exchanges implemented in the early 2000s. During the 
portions of their studies when modern harm reduction measures were in effect, Bruneau 
et al found that among a population of PWID in Montreal, regular injection drug use was 
associated with an incidence of  1.53 new cases of HIV per 100 P-Y;116 while Des Jarlais 
et al found an HIV incidence of 1.77/100 P-Y among PWID in New York.117 Although 
more recent local data on HIV incidence among PWID are unavailable and are urgently 
needed, the average of these two rates provides an estimate of 1.65/100 person-years as 
the baseline event rate for HIV seroconversion in this study. Assuming the same study 
parameters as before with a mean follow up period of three years and a censoring rate of 
0.5, 1391 HIV-negative participants would be needed for the HIV subanalysis. 
Accounting for the 2.147% of PWID who are already HIV positive118 and would 
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therefore be excluded from this analysis gives a final sample size of 1391/(1-0.02147) = 
1422 participants. 
 
Meanwhile, HCV incidence is much higher among PWID, ranging from 10 to 40 per 100 
person-years in different studies according to Hagan et al.119 Using the smaller of 
Hagan’s values for a more conservative result, we can estimate that HCV seroconversion 
rates would drop from 10 per 100 person years to 3.1 per 100 person years among more 
frequent SIF users. With a censoring rate of 0.5 and a follow up period of three years, 
only 248 participants would be needed to confirm a 69% decrease in HCV incidence for 
frequent SIF users relative to infrequent ones. However given the 43.126% of PWID 
already infected with HCV in the US,118 248/(1-0.43126) = 436 total study participants 
would need to be observed in order to perform the HCV subanalysis. 
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